We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Exonate

News List

Exonate launches diabetic macular oedema trial pharmatimes
February 04, 2021
Cambridge, UK-based Exonate has dose the first patient with its lead compound – EXN 407 – in a Phase Ib/II clinical trial investigating the drug in volunteers with centre-involved diabetic macular oedema (CI-DMO).
Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO) prnasia
January 13, 2020
Exonate, an early stage biotechnology company, announced today that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Wellcome Trust grants funding to Exonate to develop wet AMD pharmaceutical-technology
February 09, 2017
UK-based biotechnology company Exonate has secured a Seeding Drug Discovery fund from Wellcome Trust to continue development of an eye-drop treatment for wet age-related macular degeneration (wet AMD).